A HER2(Nb)/CD3(scFv) BiTE, termed BiHC (bispecific HER2-CD3 antibody), could significantly activate T cells and increase the cytotoxicity of HER2+ tumor cells (53). The gene discussed is ERBB2; the disease is neoplasm.